




ISOQOL-NL is a Chapter of the International Society for Quality of Life Research.  
[www.isoqol.org](http://www.isoqol.org)



ISOQOL-NL is a focus group of the Dutch Epidemiological Society.  
[www.epidemiologie.nl](http://www.epidemiologie.nl)

# ISOQOL-NL

## symposium

# Interpretation of Patient-Reported Outcomes

**Friday Sep 24, 2010: 10.00 – 17.30 hr**

**Key note speaker:**

**prof. Gordon Guyatt, McMaster University, Canada**

Organized by the Dutch Chapter of ISOQOL (also a focus group of the Dutch Epidemiological Society) and the Knowledgecenter Measurement Instruments from the Department of Epidemiology and Biostatistics and the EMGO+ Institute for Health and Care Research, VU University Medical Center, Amsterdam



**Location:**

**VU Medical Center, Amsterdam  
Room: Maas - ZH 4 E 11 (4<sup>th</sup> floor)**

**Costs: €50 (including lunch and drinks)**



**Registration:**

**[www.gezondheidstoestand.nl](http://www.gezondheidstoestand.nl) or  
[gezondheidstoestand@gmail.com](mailto:gezondheidstoestand@gmail.com)**

## **Program: Interpretation of Patient-Reported Outcomes (PROs)**

10.00-10.30	Registration and coffee
10.30-11.00	Maarten Boers – Combining harm and benefit in clinical trials in one scale – an example from OMERACT
11.00-11.30	Sandra Beurskens – Using PROs in clinical practice
11.30-12.00	Dolf de Boer – Using PROs as an indicator of quality of care
12.00-12.15	Discussion time
<b>12.15-13.15</b>	<b>Lunch</b>
13.15-14.00	Gordon Guyatt – Making quality of life outcomes in clinical trials more interpretable to clinicians
14.00-14.15	Jaap Sont– Analyzing a clinical trial with the responder analysis suggested by Guyatt
14.15-14.45	Nick Henschke – Variations in use of responder analyses in clinical trials
14.45-15.15	Discussion time
<b>15.15-15.45</b>	<b>Break</b>
15.45-16.05	Raymond Ostelo – Using Global Perceived Effect scales – questioning their validity?
16.05-16.25	Peter ten Klooster – Using IRT modeling to measure disability across different diseases: an example with the HAQ-DI
16.25-16.45	Discussion time
<b>16.45-17.30</b>	<b>Drinks</b>

### **Prof. dr. Gordon Guyatt,**

Department of Clinical Epidemiology & Biostatistics and Department of Medicine, McMaster University, Hamilton, Canada

Gordon Guyatt is internationally recognized for his work on evidence-based medicine. He is acknowledged by the Web of Science as one of the 250 most cited authors worldwide. He is (co)author of more than 600 publications (H-index of 98), of which 135 on the measurement of PROs, mostly methodological. His contribution to quality of life research, randomized trials and meta-analysis have been considered groundbreaking.

### **Making quality of life outcomes in clinical trials more interpretable to clinicians**

To make optimal use of data from randomized trials in clinical decision-making, clinicians require knowledge of the magnitude of treatment effects. Reports of trials including quality of life data often fail to report results that provide interpretable estimates of magnitude of effect. Strategies that investigators could use to remedy this problem include reporting mean differences between groups in relation to the minimal important difference and reporting the proportion of patients who benefit from treatment and the associated number needed to treat. Techniques are available that allow investigators to use the same strategies in reporting pooled estimates from meta-analyses even when studies use different instruments to measure the same construct.